SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes.
Huan ChenYochai BirnbaumRegina YeHsiu-Chiung YangMandeep BajajYumei YePublished in: Cardiovascular drugs and therapy (2021)
Dapagliflozin reduced ketone body levels and attenuated the activation of NFκB and the activation of the inflammasome in T1DM mice with ketoacidosis.